Current clinical trials

Current clinical trials

Kidney cancer


  • Keynote 564

    A phase III, randomised, double-blind, placebo-controlled clinical trial of Pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (KEYNOTE-564):


  • Checkmate-9ER

    A study of Nivolumab combined with Cabozantinib or Nivolumab and Ipilimumab combined with Cabozantinib compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 9ER):


    A multicenter, open-label, randomised, phase 3 trial to compare the efficacy and safety of Lenvatinib in combination with Everolimus or Pembrolizumab versus Sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma (CLEAR):


    A randomised, double-blind, placebo-controlled phase 2 study comparing CB-839 in combination with Cabozantinib (CB-Cabo) versus placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Bladder cancer

Adjuvant / Neoadjuvant:

    Phase III, randomized, open-Label, multi-center, global study to determine the efficacy and safety of Durvalumab in combination With Gemcitabine+Cisplatin for neoadjuvant treatment followed by Durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer:


  • Javelin Bladder 100

    A phase 3, multicenter, multinational, randomised, open-label, parallel-arm study of Avelumab* (Msb0010718c) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy:

  • FORT-1

    A randomised, open label, multicenter phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy:

  • NILE
    A phase III, randomized, open-label, controlled, multi-center, global study of first-line Durvalumab in combination with standard of care chemotherapy and Durvalumab in combination with Tremelimumab and standard of care chemotherapy versus standard of care chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer:

Breast cancer

  • No trials currently recruiting

Prostate cancer



  • IPATential 150

    A phase III, randomised, double-blind, placebo-controlled, multicenter trial testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, relative to placebo plus Abiraterone plus Prednisone/Prednisolone in adult male patients with Asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer: 

  • JPCM
    Phase 2, randomized, double-blind, placebo-controlled study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in patients with metastatic castration-resistant prostate cancer:

Multi-tumour trials

  • Javelin Medley

    A phase 1b/2 open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of Avelumab* (Msb0010718c) in combination with other cancer immunotherapies In patients with advanced malignancies:

  • Javelin PARP Medley

    A phase 1b/2 dose-finding and proof-of-concept (Poc) study to evaluate safety and anti-tumor activity of Avelumab in combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (Parp) inhibitor Talazoparib In patients with locally advanced or metastatic solid tumors:

Gastrointestinal cancer



Germ cell cancer

  • P3BEP

    Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours:


  • No trials currently recruiting



    Observational study of obstructive lung disease (NOVELTY): A NOVEL observational longiTudinal studY on patients with a diagnosis or suspected diagnosis of asthma and/or COPD to describe patient characteristics, treatment patterns and the burden of illness over time and to identify phenotypes and endotypes associated with differential outcomes that may support future development of personalized treatment strategies:


  • No trials currently recruiting


Content owner: Medicine and Health Sciences Last updated: 21 Feb 2019 1:37pm

Back to the top of this page